- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05557474
Development and Clinical Validation of Early-stage Lung Cancer Prognostic Kit
Development and Clinical Validation of Early-stage Lung Cancer Prognostic Kit and Immunotherapy Companion Diagnostic Laboratory Developed Tests
Lung cancer is the leading cause of cancer mortality worldwide in spite of the advanced progresses in medication and low-dose CT screening. The early-stage lung cancer accounts for less than 50% of newly diagnosed lung cancer in Taiwan, even in stage IB patients proximately 30% still suffer from recurrence and metastasis.
The International Cancer Moonshot Project recently established the first comprehensive proteogenomics profiling of early-stage lung cancer patients in East Asia, revealing a proteomics-informed classification to identify a new "late like" subtype, which can identify a subgroup of early-stage patients with worse clinicopathological features (Cell, Cover story, 2020). This study has been featured in prestigious journals (Nat Rev Clin Oncol; Cancer Discov, 2020) and led to two provisional US patents. In this proposal, taking the discovery from the Cancer Moonshot multiomics database, the investigators aim to translate these findings into clinical utilities. Two subprojects are proposed. (1) Validation of "late-like" protein markers for identifying high-risk early-stage lung cancer: Two IVD kits will be developed, including high-risk early-stage lung cancer IHC prediction kit for tumor staining and high-risk early lung cancer ELISA prediction kit for noninvasive diagnosis. (2) Conducting a prospective clinical trial to evaluate the accuracy of high-risk early-stage lung cancer IHC prediction kit and high-risk early-stage lung cancer ELISA prediction kit.
Study Overview
Status
Conditions
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: GeeChen Chang, MD. PhD
- Phone Number: 34414 +886-4-24739595
- Email: geechen@gmail.com
Study Locations
-
-
-
Taichung, Taiwan, 402
- Recruiting
- Chung Shan Medical University Hospital
-
Contact:
- GEECHEN CHANG, MD, PhD
- Phone Number: 34414 +886-4-24739595
- Email: geechen@gmail.com, cshy1888@csh.org.tw
-
Taipei, Taiwan, 106
- Recruiting
- National Taiwan University, Cancer Center
-
Contact:
- Jin-Shing Chen, MD PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Willing to sign and provide subject consent.
- Male or female of age 20 or older.
- Patients diagnosed with lung adenocarcinoma by tumor pathology.
- Lung cancer with the pathological stage of IA/IB/II/IIIA according to the American Joint Committee on Cancer Staging Manual (8th Edition).
- Complete tumor resection (R0 resection).
- The East Coast Cancer Clinical Research Collaborative (ECOG) performance status was 0 or 1 at the time of grouping.
- Those willing to provide tumor tissue or cytology specimens (including surgical specimens, tissue biopsy specimens, or cytology specimens), blood and body fluid specimens (for follow-up or disease recurrence, such as urine, malignant pleural effusion, ascites, pericardial fluid, etc.).
Exclusion Criteria:
- Not primary lung cancer patients.
- Lung cancer patients whose pathological stage is not IA/IB/II/IIIA according to the American Joint Committee on Cancer Staging Manual (8th Edition) after surgery.
- Patients with uncontrolled malignant tumors other than lung cancer.
- Uncontrolled systemic disease (such as diabetes, hypertension, active infection, etc.) (determined by the principal investigator )
- Pregnant women.
- Any condition may put the patient at serious risk, may affect the interpretation of the trial results, or may seriously interfere with the patient's participation in the trial.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Lung cancer post surgery recurrence follow up
Lung adenocarcinoma, stage IA/IB/II/IIIA post-surgery follow up
|
blood sample with ELISA
surgical tumor part with IHC
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
disease free survival
Time Frame: 5 years
|
Disease free survival
|
5 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall survival
Time Frame: 10 years
|
10 years
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
General Publications
- Yarchoan M, Johnson BA 3rd, Lutz ER, Laheru DA, Jaffee EM. Targeting neoantigens to augment antitumour immunity. Nat Rev Cancer. 2017 Apr;17(4):209-222. doi: 10.1038/nrc.2016.154. Epub 2017 Feb 24. Erratum In: Nat Rev Cancer. 2017 Aug 24;17 (9):569.
- Galon J, Bruni D. Tumor Immunology and Tumor Evolution: Intertwined Histories. Immunity. 2020 Jan 14;52(1):55-81. doi: 10.1016/j.immuni.2019.12.018.
- Chen YJ, Roumeliotis TI, Chang YH, Chen CT, Han CL, Lin MH, Chen HW, Chang GC, Chang YL, Wu CT, Lin MW, Hsieh MS, Wang YT, Chen YR, Jonassen I, Ghavidel FZ, Lin ZS, Lin KT, Chen CW, Sheu PY, Hung CT, Huang KC, Yang HC, Lin PY, Yen TC, Lin YW, Wang JH, Raghav L, Lin CY, Chen YS, Wu PS, Lai CT, Weng SH, Su KY, Chang WH, Tsai PY, Robles AI, Rodriguez H, Hsiao YJ, Chang WH, Sung TY, Chen JS, Yu SL, Choudhary JS, Chen HY, Yang PC, Chen YJ. Proteogenomics of Non-smoking Lung Cancer in East Asia Delineates Molecular Signatures of Pathogenesis and Progression. Cell. 2020 Jul 9;182(1):226-244.e17. doi: 10.1016/j.cell.2020.06.012.
- Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins TBK, Veeriah S, Shafi S, Johnson DH, Mitter R, Rosenthal R, Salm M, Horswell S, Escudero M, Matthews N, Rowan A, Chambers T, Moore DA, Turajlic S, Xu H, Lee SM, Forster MD, Ahmad T, Hiley CT, Abbosh C, Falzon M, Borg E, Marafioti T, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Shah R, Joseph L, Quinn AM, Crosbie PA, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Dentro S, Taniere P, O'Sullivan B, Lowe HL, Hartley JA, Iles N, Bell H, Ngai Y, Shaw JA, Herrero J, Szallasi Z, Schwarz RF, Stewart A, Quezada SA, Le Quesne J, Van Loo P, Dive C, Hackshaw A, Swanton C; TRACERx Consortium. Tracking the Evolution of Non-Small-Cell Lung Cancer. N Engl J Med. 2017 Jun 1;376(22):2109-2121. doi: 10.1056/NEJMoa1616288. Epub 2017 Apr 26.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 110WFD2510303
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrence
-
Portuguese Oncology Institute, CoimbraCompletedColorectal Cancer | Recurrence, Local NeoplasmPortugal
-
Chinese PLA General HospitalRecruitingHCC | Recurrence TumorChina
-
Paracelsus Medical UniversityHeinrich-Heine University, Duesseldorf; Poznan University of Medical Sciences; University Hospital of Ferrara and other collaboratorsCompletedToxicity | Local Neoplasm RecurrenceAustria
-
General Hospital GroeningeUniversitaire Ziekenhuizen KU Leuven; Jessa Hospital; University Hospital, Ghent and other collaboratorsNot yet recruiting
-
Dallas VA Medical CenterTerminatedSolid Tumors | Cancer RecurrenceUnited States
-
The University of Hong KongHealth and Medical Research FundNot yet recruitingCancer | Fear of Cancer Recurrence
-
German Centre for Assessment and Evaluation of...Not yet recruitingComplication | Continence | Potency | Biochemical RecurrenceGermany
-
The University of Hong KongNot yet recruitingCancer | Fear of Cancer Recurrence
-
RottapharmTerminatedHCV Recurrence After Liver Transplantation
-
The University of Hong KongHealth and Medical Research FundRecruitingCancer | Fear of Cancer Recurrence | PsychooncologyHong Kong
Clinical Trials on Early-stage lung cancer prognostic kit -- ELISA
-
Peking University People's HospitalUnknown
-
Ugo PastorinoIstituto Oncologico Veneto IRCCS; San Luigi Gonzaga Hospital; Azienda Ospedaliero-Universitaria... and other collaboratorsRecruitingCardiovascular Diseases | Lung Cancer | COPD (Chronic Obstructive Pulmonary Disease) With Acute Lower Respiratory InfectionItaly
-
National Jewish HealthCompletedHigh Risk of Developing Lung CancerUnited States
-
Medical University of South CarolinaMayo ClinicTerminated
-
NYU Langone HealthCompleted
-
Dartmouth-Hitchcock Medical CenterPatient-Centered Outcomes Research Institute; Washington University School... and other collaboratorsCompleted
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI); Indiana University; Kaiser Permanente; University...WithdrawnSmoking | Lung Cancer | Smoking, Tobacco | Smoking, CigaretteUnited States
-
Istanbul UniversityRecruitingEndometrial Cancer | Sentinel Lymph NodeTurkey
-
Braintree LaboratoriesCompletedColonoscopyUnited States
-
UNICANCERDaiichi Sankyo Europe, GmbH, a Daiichi Sankyo CompanyActive, not recruiting